
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc is well-positioned for positive stock performance due to anticipated accelerated growth in the spine market and strong sales in its Enabling Technologies segment, which should contribute to favorable margins. Recent performance metrics reveal a robust 10% growth in Nevro sales, primarily driven by solid U.S. spine performance, suggesting significant market traction that may enhance future revenue streams. Additionally, the company's focus on integrating NuVasive and improving manufacturing efficiency is expected to bolster its EBITDA margins to stabilize between 34-35% by 2026, providing a strong foundation for sustainable organic growth and improved free cash flow.
Bears say
Globus Medical faces a negative outlook primarily due to several identified risks, including slower-than-anticipated growth in the spine market and potential revenue disruptions stemming from recent mergers involving NuVasive and Nevro. Additionally, the company's bear case scenario hinges on a significant deceleration in revenue growth to the low-single digits and challenges related to the execution of new product launches and market expansion, which could hinder expected contributions from musculoskeletal products. Furthermore, potential declines in operating margins coupled with a stagnant capital environment for robotic purchasing could exacerbate the company's financial challenges.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares